{
  "id": "604cda0994d57fd879000002",
  "type": "summary",
  "question": "Explain the action of Balovaptan.",
  "ideal_answer": "Balovaptan is a low-molecular-weight, orally active, hydrophilic non-peptide molecule that blocks Vasopressin-1a. It is approved for the treatment of autism spectrum disorders (ASD).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32935287",
    "http://www.ncbi.nlm.nih.gov/pubmed/31951127",
    "http://www.ncbi.nlm.nih.gov/pubmed/31043521"
  ],
  "snippets": [
    {
      "text": "Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951127",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Balovaptan, an investigational vasopressin 1a receptor antagonist that has been evaluated for improvement of social communication and interaction,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32935287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "balovaptan, an orally administered selective vasopressin V1a receptor antagonis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31043521",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Balovaptan, an investigational vasopressin 1a receptor antagonist that has been evaluated for improvement of social communication and interaction, is primarily metabolized by cytochrome P450 3A4 (CYP3A4).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32935287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Balovaptan, an investigational vasopressin 1a receptor antagonist that has been evaluated for improvement of social communication and interaction, is primarily metabolized by cytochrome P450 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32935287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ek clinical phase 2 study in adults with autism spectrum disorder balovaptan demonstrated improvements in Vineland-II Adaptive Behavior Scales, a secondary end point comprising communication, socialization, and daily living skills. Balovaptan ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951127",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Balovaptan, an investigational vasopressin 1a receptor antagonist that has been evaluated for improvement of social communication and interaction, is primarily metabolized by cytochrome P450 3A4",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32935287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a 12-week clinical phase 2 study in adults with autism spectrum disorder balovaptan demonstrated improvements in Vineland-II Adaptive Behavior Scales, a secondary end point comprising communication, socialization, and daily living skills.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31951127",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Balovaptan, an investigational vasopressin 1a receptor antagonist that has been evaluated for improvement of social communication and interaction, is primarily metabolized by cytochrome P450 3A4 (CYP3A4).METHODS: Two single-center, non-randomized, two-period, phase 1 studies assessed the effect of the strong CYP3A4 inhibitor itraconazole (study NCT03579719) or the strong CYP3A4 inducer rifampicin (study NCT03586726) at steady state on the pharmacokinetics (PK) of steady-state balovaptan",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32935287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results support further study of balovaptan as a potential treatment for the socialization and communication deficits in ASD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31043521",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}